212 related articles for article (PubMed ID: 8815166)
21. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
[TBL] [Abstract][Full Text] [Related]
22. The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred.
Sawle GV; Wroe SJ; Lees AJ; Brooks DJ; Frackowiak RS
Ann Neurol; 1992 Nov; 32(5):609-17. PubMed ID: 1449241
[TBL] [Abstract][Full Text] [Related]
23. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
[TBL] [Abstract][Full Text] [Related]
24. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
[TBL] [Abstract][Full Text] [Related]
25. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study.
Brooks DJ; Playford ED; Ibanez V; Sawle GV; Thompson PD; Findley LJ; Marsden CD
Neurology; 1992 Aug; 42(8):1554-60. PubMed ID: 1641153
[TBL] [Abstract][Full Text] [Related]
26. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study.
Ghaemi M; Raethjen J; Hilker R; Rudolf J; Sobesky J; Deuschl G; Heiss WD
Mov Disord; 2002 Jul; 17(4):782-8. PubMed ID: 12210876
[TBL] [Abstract][Full Text] [Related]
27. Dopa-responsive dystonia: [18F]dopa positron emission tomography.
Sawle GV; Leenders KL; Brooks DJ; Harwood G; Lees AJ; Frackowiak RS; Marsden CD
Ann Neurol; 1991 Jul; 30(1):24-30. PubMed ID: 1681782
[TBL] [Abstract][Full Text] [Related]
28. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
[TBL] [Abstract][Full Text] [Related]
29. Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.
Otsuka M; Ichiya Y; Hosokawa S; Kuwabara Y; Tahara T; Fukumura T; Kato M; Masuda K; Goto I
J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):898-904. PubMed ID: 1744644
[TBL] [Abstract][Full Text] [Related]
30. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants.
Sawle GV; Bloomfield PM; Björklund A; Brooks DJ; Brundin P; Leenders KL; Lindvall O; Marsden CD; Rehncrona S; Widner H
Ann Neurol; 1992 Feb; 31(2):166-73. PubMed ID: 1575455
[TBL] [Abstract][Full Text] [Related]
31. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
32. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
33. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
Nurmi E; Ruottinen HM; Bergman J; Haaparanta M; Solin O; Sonninen P; Rinne JO
Mov Disord; 2001 Jul; 16(4):608-15. PubMed ID: 11481683
[TBL] [Abstract][Full Text] [Related]
34. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
35. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
[TBL] [Abstract][Full Text] [Related]
36. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.
Burn DJ; Sawle GV; Brooks DJ
J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):278-84. PubMed ID: 8158173
[TBL] [Abstract][Full Text] [Related]
38. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease.
Morrish PK; Sawle GV; Brooks DJ
Brain; 1996 Dec; 119 ( Pt 6)():2097-103. PubMed ID: 9010013
[TBL] [Abstract][Full Text] [Related]
39. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
Thobois S; Ribeiro MJ; Lohmann E; Dürr A; Pollak P; Rascol O; Guillouet S; Chapoy E; Costes N; Agid Y; Remy P; Brice A; Broussolle E;
Arch Neurol; 2003 May; 60(5):713-8. PubMed ID: 12756135
[TBL] [Abstract][Full Text] [Related]
40. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
